A plea for the biopsy marker: how, why and why not clipping after breast biopsy?

Abstract:

:In the last decade, percutaneous breast biopsies have become a standard for the management of breast diseases. Biopsy clips allow for precise lesion localization, thus minimizing the volume of breast to be resected at the time of surgery. With the development of many imaging techniques (including mammography, sonography, and breast magnetic resonance imaging), one of the challenges of the multidisciplinary became to synthesize all informations obtained from the various imaging procedures. The use of biopsy markers after percutaneous biopsy is one of the keys for optimal patient management, helping the radiologist to deal with multiple lesions, to insure correlation across different imaging modalities and to follow-up benign lesions, helping the oncologist by marking a tumor prior to neoadjuvant chemotherapy, helping the surgeon by facilitating preoperative needle localization, to precisely mark the margins of extensive disease and to guide intraoperative tumor resection, and helping the pathologist to insure the lesion of interest has been removed and to identify the region of interest in a mastectomy specimen. We believe biopsy clip markers should be deployed after all percutaneous interventions and present in this review the arguments to support this statement. Minimal indications for clip deployment will also be detailed.

authors

Thomassin-Naggara I,Lalonde L,David J,Darai E,Uzan S,Trop I

doi

10.1007/s10549-011-1847-x

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

881-93

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

132

pub_type

杂志文章,评审
  • Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor.

    abstract::The Gail model is considered the best available means for estimating risk of breast cancer development, but it has not yet been applied systematically and validated in Turkish female population. This study was designed to evaluate the performance of the Gail model for Turkish female population. Additionally duration o...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-009-0541-8

    authors: Ulusoy C,Kepenekci I,Kose K,Aydintug S,Cam R

    更新日期:2010-04-01 00:00:00

  • Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

    abstract::We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01833345

    authors: Reid AD,Horobin JM,Newman EL,Preece PE

    更新日期:1992-01-01 00:00:00

  • Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

    abstract:BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9492-5

    authors: Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

    更新日期:2007-12-01 00:00:00

  • Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.

    abstract:PURPOSE:Nearly half of the 3.5 million female breast cancer survivors in the US are aged 65 years or older at diagnosis, yet little is known about associations of obesity and physical activity with breast cancer-specific mortality (BCSM) among older survivors. METHODS:Between 1992 and 2013, 5254 women in the Cancer Pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4470-7

    authors: Maliniak ML,Patel AV,McCullough ML,Campbell PT,Leach CR,Gapstur SM,Gaudet MM

    更新日期:2018-01-01 00:00:00

  • Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

    abstract::Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023918026437

    authors: Barlow J,Yandell D,Weaver D,Casey T,Plaut K

    更新日期:2003-05-01 00:00:00

  • Tamoxifen aziridine binding to cytosolic proteins from human breast specimens is negatively associated with estrogen receptors, progesterone receptors, pS2, and cathepsin-D.

    abstract::[3H]Tamoxifen Aziridine ([3H]TAZ) is a derivative of the antiestrogen tamoxifen that covalently labels the Estrogen Receptor (ER), and perhaps other uncharacterized proteins. In a previous article we described that [3H]TAZ binds to a cytosolic protein from human uterine tissues that shares some, but not all, the ER pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006062510883

    authors: Navarro D,Doreste H,Cabrera JJ,Morales M,Díaz-Chico JC,Díaz-Chico BN

    更新日期:1998-07-01 00:00:00

  • Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.

    abstract::Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of c...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01806692

    authors: Casper ES,Guidera CA,Bosl GJ,Hakes TB,Kaufman RJ,Shurgot B,Kinne DW

    更新日期:1987-01-01 00:00:00

  • Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

    abstract::Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665803

    authors: Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

    更新日期:1993-01-01 00:00:00

  • Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.

    abstract::From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin. Patients were eligible if they had progressive disease after either adjuvant (2 patients) or previous chemoth...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01806146

    authors: Colozza M,Gori S,Mosconi AM,Anastasi P,Basurto C,Ludovini V,De Angelis V,Giansanti M,Tonato M

    更新日期:1996-01-01 00:00:00

  • Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.

    abstract::Neurotoxicity is a common side-effect during taxane therapy. The prevalence and severity of long-term neurotoxicity following therapy is unknown. The authors conducted a cross-sectional study of 50 consecutive patients with stage I-III BC, who were within 6 months and 2 years of completing adjuvant taxane therapy and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1278-0

    authors: Hershman DL,Weimer LH,Wang A,Kranwinkel G,Brafman L,Fuentes D,Awad D,Crew KD

    更新日期:2011-02-01 00:00:00

  • Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

    abstract:PURPOSE:Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on abs...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05106-7

    authors: Patel DA,Xi J,Luo J,Hassan B,Thomas S,Ma CX,Campian JL

    更新日期:2019-04-01 00:00:00

  • Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin.

    abstract::Serum melatonin (MLT) levels have been reported to diminish significantly by the 5th and 6th decades of life as the incidence of breast cancer increases. Given MLT's anti-cancer activity, we hypothesize that age-related decline in pineal MLT production leads to enhanced breast cancer development and growth as women ag...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0958-0

    authors: Hill SM,Cheng C,Yuan L,Mao L,Jockers R,Dauchy B,Frasch T,Blask DE

    更新日期:2011-05-01 00:00:00

  • Energy balance in early breast cancer patients receiving adjuvant chemotherapy.

    abstract::Weight gain is a common problem amongst women receiving adjuvant chemotherapy for early breast cancer. We undertook a study to determine the causes of this weight gain. Prospective measurements of body mass and composition (skinfolds, bioelectrical impedance, total body potassium), energy balance (resting energy expen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000014037.48744.fa

    authors: Harvie MN,Campbell IT,Baildam A,Howell A

    更新日期:2004-02-01 00:00:00

  • Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.

    abstract::WWOX is a cancer gene, spanning the common chromosomal fragile site 16D. Genomic and expression aberrations affecting this gene and locus are common in various neoplasias including breast cancer. The aim of the present study was to evaluate the relationship between WWOX expression at the protein level with respect to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-1474-x

    authors: Nunez MI,Ludes-Meyers J,Abba MC,Kil H,Abbey NW,Page RE,Sahin A,Klein-Szanto AJ,Aldaz CM

    更新日期:2005-01-01 00:00:00

  • Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

    abstract::The Women's Health Initiative (WHI) randomized trials found that use of combined estrogen and progestin menopausal hormone therapy (CHT) increases breast cancer risk, but use of unopposed estrogen hormone therapy (EHT) does not. However, several questions regarding the impact of hormone use on risk of different types ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2960-4

    authors: Li CI,Daling JR,Haugen KL,Tang MT,Porter PL,Malone KE

    更新日期:2014-06-01 00:00:00

  • Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.

    abstract::Aromatase inhibitors (AIs) are used for treatment of estrogen receptor α (ER)-positive breast cancer; however, resistance is a major obstacle for optimal outcome. This preclinical study aimed at identifying potential new treatment targets in AI-resistant breast cancer cells. Parental MCF-7 breast cancer cells and four...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3284-8

    authors: Hole S,Pedersen AM,Lykkesfeldt AE,Yde CW

    更新日期:2015-02-01 00:00:00

  • Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial.

    abstract::The aim of this study was to evaluate the effectiveness of an additional, individualized, multi-component complementary medicine treatment offered to breast cancer patients at the Merano Hospital (South Tyrol) on health-related quality of life compared to patients receiving usual care only. A randomized pragmatic tria...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-014-3249-3

    authors: Witt CM,Außerer O,Baier S,Heidegger H,Icke K,Mayr O,Mitterer M,Roll S,Spizzo G,Scherer A,Thuile C,Wieser A,Schützler L

    更新日期:2015-01-01 00:00:00

  • Mutation analysis of PALB2 gene in French breast cancer families.

    abstract::Several population-based and family-based studies have demonstrated that germline mutations of the PALB2 gene (Partner and Localizer of BRCA2) are associated with an increased risk of breast cancer. Distinct mutation frequencies and spectrums have been described depending on the population studied. Here we describe th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3625-7

    authors: Damiola F,Schultz I,Barjhoux L,Sornin V,Dondon MG,Eon-Marchais S,Marcou M,GENESIS Study Investigators.,Caron O,Gauthier-Villars M,de Pauw A,Luporsi E,Berthet P,Delnatte C,Bonadona V,Maugard C,Pujol P,Lasset C,Longy M

    更新日期:2015-12-01 00:00:00

  • Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.

    abstract:BACKGROUND:The aim was to prove the low identification rate of sentinel lymph node biopsy (SNB) and to determine the feasibility of replacing axillary lymph node dissection (AND) in axillary lymph node positive patients after chemotherapy. METHODS:From October 2001 to July 2005, 875 consecutive patients with primary o...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-006-9330-9

    authors: Lee S,Kim EY,Kang SH,Kim SW,Kim SK,Kang KW,Kwon Y,Shin KH,Kang HS,Ro J,Lee ES

    更新日期:2007-05-01 00:00:00

  • Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

    abstract::The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s10549-018-05105-8

    authors: Nitz U,Gluz O,Christgen M,Kates RE,Clemens M,Malter W,Nuding B,Aktas B,Kuemmel S,Reimer T,Stefek A,Lorenz-Salehi F,Krabisch P,Just M,Augustin D,Liedtke C,Chao C,Shak S,Wuerstlein R,Kreipe HH,Harbeck N

    更新日期:2019-05-01 00:00:00

  • Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women.

    abstract::The relationship between IGF genotypes and phenotypes in breast tumors and their associations with breast cancer risk remain to be elucidated. Such information is especially scarce in Chinese women. To evaluate IGF-I and IGFBP-3 genotypes in relation to their phenotypes in local breast tissues and in association with ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1552-9

    authors: Qian B,Zheng H,Yu H,Chen K

    更新日期:2011-11-01 00:00:00

  • Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer.

    abstract:PURPOSE:To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician. PATIENTS AND METHODS:Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized pha...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1006483214678

    authors: Okamura H,Yamamoto N,Watanabe T,Katsumata N,Takashima S,Adachi I,Kugaya A,Akechi T,Uchitomi Y

    更新日期:2000-05-01 00:00:00

  • HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

    abstract:BACKGROUND:Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-019-05303-y

    authors: Jerusalem G,Lancellotti P,Kim SB

    更新日期:2019-09-01 00:00:00

  • Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer.

    abstract::Fibroblast growth factor receptor 2 is a tyrosine kinase receptor that is a member of the family of individually distinct fibroblast growth factor receptors involved in cell proliferation, invasiveness, motility, and angiogenesis. Genome-wide association studies have identified FGFR2 as a breast cancer (BC) susceptibi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0872-5

    authors: Jia C,Cai Y,Ma Y,Fu D

    更新日期:2010-11-01 00:00:00

  • Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.

    abstract:PURPOSE:Triple-negative breast cancers (TNBC) are aggressive tumours that exhibit abundant lymphoid infiltrates which modulate tumour behaviour. Recent findings suggest that TNBC with higher densities of plasma cells are associated with a favourable prognosis, and tertiary lymphoid structures (TLS) have prognostic sign...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05548-y

    authors: Seow DYB,Yeong JPS,Lim JX,Chia N,Lim JCT,Ong CCH,Tan PH,Iqbal J

    更新日期:2020-04-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

    abstract:PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-020-05626-1

    authors: Watanabe J,Saito M,Horimoto Y,Nakamoto S

    更新日期:2020-05-01 00:00:00

  • Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS).

    abstract::Management of localized breast cancer now commonly involves a breast-sparing approach combined with systemic adjuvant therapy resulting in improved cosmetic results and patient survival. Reducing dietary fat intake represents a conceptually new approach to further improve outcome of patients with resected breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01834637

    authors: Chlebowski RT,Rose D,Buzzard IM,Blackburn GL,Insull W Jr,Grosvenor M,Elashoff R,Wynder EL

    更新日期:1992-01-01 00:00:00

  • Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

    abstract::Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2791-8

    authors: García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

    更新日期:2014-01-01 00:00:00

  • Management of brain metastases in breast cancer: a review of current practices and emerging treatments.

    abstract:PURPOSE:Breast cancer brain metastases (BCBM) are becoming an increasingly common diagnosis due to improved systemic control and more routine surveillance imaging. Treatment continues to require a multidisciplinary approach managing systemic and intracranial disease burden. Although, improvements have been made in the ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-05552-2

    authors: Mills MN,Figura NB,Arrington JA,Yu HM,Etame AB,Vogelbaum MA,Soliman H,Czerniecki BJ,Forsyth PA,Han HS,Ahmed KA

    更新日期:2020-04-01 00:00:00